Literature DB >> 21514280

Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.

Zhen-Ning Tang1, Fan Zhang, Peng Tang, Xiao-Wei Qi, Jun Jiang.   

Abstract

Receptor activator of NF-κB (RANK) and RANK ligand (RANKL) are known to play an important role in the development and progression of breast cancer. However, the mechanisms by which stimuli regulate the expression of RANK and RANKL in breast cancer cells are largely unknown. In this study, we show that hypoxia, a common feature of malignant tumors, can enhance the expression of RANK and RANKL mRNA and protein in MDA-MB-231 and MCF-7 breast cancer cells. In addition, we found that hypoxia induced hypoxia-inducible factor-1 alpha (HIF-1α) and phosphorylation of Akt, resulting in upregulation of RANK and RANKL expression; HIF-1α-targeted siRNA and PI3K-Akt inhibitor abrogated this upregulation in MDA-MB-231 cells. Furthermore, we also observed that hypoxia accelerated RANKL-mediated cell migration, which was inhibited following HIF-1α knockdown and PI3K-Akt inhibition. Thus, we provide evidence that hypoxia upregulates RANK and RANKL expression and increases RANKL-induced cell migration via the PI3K/Akt-HIF-1α pathway.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514280     DOI: 10.1016/j.bbrc.2011.04.035

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Quantification of cell fusion events human breast cancer cells and breast epithelial cells using a Cre-LoxP-based double fluorescence reporter system.

Authors:  Marieke Mohr; Songül Tosun; Wolfgang H Arnold; Frank Edenhofer; Kurt S Zänker; Thomas Dittmar
Journal:  Cell Mol Life Sci       Date:  2015-04-22       Impact factor: 9.261

2.  Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE(2), and MMP-13 expression.

Authors:  Zhi-feng Wei; Xiao-lan Jiao; Ting Wang; Qian Lu; Yu-feng Xia; Zheng-tao Wang; Qing-long Guo; Gui-xin Chou; Yue Dai
Journal:  Acta Pharmacol Sin       Date:  2013-02-11       Impact factor: 6.150

3.  Digoxin Attenuates Receptor Activation of NF-κB Ligand-Induced Osteoclastogenesis in Macrophages.

Authors:  Kimihiro Igari; Matthew J Kelly; Dai Yamanouchi
Journal:  J Vasc Res       Date:  2019-05-14       Impact factor: 1.934

Review 4.  Targeting RANKL in metastasis.

Authors:  William C Dougall; Ingunn Holen; Eva González Suárez
Journal:  Bonekey Rep       Date:  2014-04-09

5.  Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.

Authors:  Valerie A Siclari; Khalid S Mohammad; Douglas R Tompkins; Holly Davis; C Ryan McKenna; Xianghong Peng; Lisa L Wessner; Maria Niewolna; Theresa A Guise; Attaya Suvannasankha; John M Chirgwin
Journal:  Breast Cancer Res       Date:  2014-12-02       Impact factor: 6.466

Review 6.  Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.

Authors:  Dominique Heymann
Journal:  J Bone Oncol       Date:  2012-04-26       Impact factor: 4.072

7.  The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.

Authors:  Lingyun Zhang; Yuee Teng; Yibo Fan; Yan Wang; Wei Li; Jing Shi; Yanju Ma; Ce Li; Xiaonan Shi; Xiujuan Qu; Yunpeng Liu
Journal:  Oncotarget       Date:  2015-09-08

Review 8.  Implications of Hypoxia in Breast Cancer Metastasis to Bone.

Authors:  Daniele M Gilkes
Journal:  Int J Mol Sci       Date:  2016-09-30       Impact factor: 5.923

9.  Molecular basis of 'hypoxic' breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling.

Authors:  Sheeja Aravindan; Mohan Natarajan; Terence S Herman; Vibhudutta Awasthi; Natarajan Aravindan
Journal:  Radiat Oncol       Date:  2013-03-04       Impact factor: 3.481

10.  Chronic inflammation in cancer development.

Authors:  Gabriele Multhoff; Michael Molls; Jürgen Radons
Journal:  Front Immunol       Date:  2012-01-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.